Aetna Abatacept (Orencia) Coverage Update

Coverage Criteria for Abatacept (Orencia)

Initial Therapy - Rheumatoid Arthritis

Covered when ALL of the following are met for initial approval (Rheumatoid arthritis adults):

RA initial approval - prior biologic/targeted synthetic: Member has previously received a biologic or targeted synthetic drug indicated for moderately to severely active rheumatoid arthritis (e.g., JAK inhibitors, TNF antagonists)

Per policy: prior receipt of a biologic/targeted synthetic qualifies

RA initial approval - biologic‑naive entry criteria

RA biomarker testing: Member has either a positive rheumatoid factor (RF) or positive anti‑cyclic citrullinated peptide (anti‑CCP) test; OR member has been tested for RF, anti‑CCP, and C‑reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)
Policy requires either a positive biomarker or comprehensive testing
RA prior methotrexate trial or exception: Member has had an inadequate response to at least a 3‑month trial of methotrexate at an adequate dose (titrated to 15 mg/week) OR has an intolerance or contraindication to methotrexate>=3 months
Appendix A lists clinical reasons to avoid methotrexate

TB screening: Documented negative tuberculosis (TB) test (PPD, IGRA, or chest x‑ray) within 6 months prior to initiating abatacept for persons naïve to biologic/targeted synthetic drugswithin 6 months

Required safety screening per policy

Initial Therapy - Articular Juvenile Idiopathic Arthritis

Covered when ANY of the following are met for articular juvenile idiopathic arthritis (members ≥2 years):

JIA initial approval - prior biologic: Member (≥2 years) has previously received a biologic or targeted synthetic drug indicated for moderately to severely active articular juvenile idiopathic arthritis

Prior biologic/targeted synthetic suffices

JIA initial approval - csDMARD failure: Member (≥2 years) has had an inadequate response to methotrexate or another conventional synthetic DMARD (e.g., leflunomide, sulfasalazine, hydroxychloroquine) given at adequate dose and duration

Adequate dose/duration per standard practice

JIA initial approval - NSAID/IA steroid + risk factor: Member (≥2 years) has had an inadequate response to scheduled NSAIDs and/or intra‑articular glucocorticoids and has ONE risk factor for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, or TMJ; erosive disease; enthesitis; delay in diagnosis; elevated inflammatory markers; symmetric disease)

Risk factors per Appendix B referenced

Initial Therapy - Psoriatic Arthritis

Covered when EITHER of the following are met for psoriatic arthritis (members ≥2 years):

PsA initial approval - prior biologic/targeted synthetic: Member (≥2 years) has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis

Prior biologic/targeted synthetic qualifies

PsA initial approval - conventional therapy failure or severe disease: For members (≥2 years) without prior biologic use: EITHER (a) mild‑to‑moderate disease with inadequate response to methotrexate, leflunomide, or another conventional synthetic DMARD at adequate dose/duration OR intolerance/contraindication to those agents OR presence of enthesitis; OR (b) member has severe psoriatic arthritis

Includes pediatric members ≥2 years; clinical activity should align with trial populations

Initial Therapy - Prophylaxis of acute GVHD

Covered when BOTH of the following are met for prophylaxis of acute GVHD:

aGVHD prophylaxis - transplant donor: Member is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or one allele‑mismatched unrelated donor

Applies to members ≥2 years as per FDA indication

aGVHD prophylaxis - concomitant regimen: Abatacept will be used in combination with a calcineurin inhibitor (e.g., cyclosporine, tacrolimus) and methotrexate as part of the prophylactic regimen

Combination regimen consistent with trial protocols and labeling

Initial Therapy - Chronic GVHD and Immune Checkpoint Inhibitor‑related Toxicity

Covered when EITHER of the following are met for chronic GVHD and checkpoint inhibitor‑related toxicity:

Chronic GVHD initial approval: Member has chronic graft‑versus‑host disease and has experienced an inadequate response to systemic corticosteroids OR has an intolerance/contraindication to systemic corticosteroids

Alternate immunosuppressant intolerance/contraindication acceptable

Checkpoint inhibitor‑related myocarditis initial approval: Member has immune checkpoint inhibitor‑related myocarditis and has experienced an inadequate response to systemic corticosteroids OR has an intolerance/contraindication to systemic corticosteroids

Indication limited to myocarditis per policy language

Continuation of Therapy

Covered for continuation when ALL of the following are met:

Continuation - RA: Member using abatacept for moderately to severely active rheumatoid arthritis (including new members) who achieves or maintains a positive clinical response as evidenced by at least 20% improvement from baseline in tender joint count, swollen joint count, pain, or disability>=20% improvement

Document objective measures of response

Continuation - JIA: Member (≥2 years) using abatacept for articular juvenile idiopathic arthritis (including new members) who achieves or maintains low disease activity or improvement in ANY of: number of joints with active arthritis, number of joints with limitation of movement, or functional ability

Improvement in any one domain supports continuation

Continuation - PsA: Member (≥2 years) using abatacept for psoriatic arthritis (including new members) who achieves or maintains low disease activity or improvement in ANY of: swollen joints, tender joints, dactylitis, enthesitis, or skin/nail involvement

Initial coverage criteria

Covered when ALL of the following are met

FDA‑approved indication: The requested use is for an FDA‑approved indication (adult RA; polyarticular JIA ≥2 years; active PsA ≥2 years; or prophylaxis of aGVHD in HSCT recipients)

See FDA‑approved indications

Clinical justification and prior therapy: Documentation of disease activity and prior therapy appropriate to the indication is provided (e.g., inadequate response, intolerance, or contraindication to conventional DMARDs and/or prior biologics/TNF antagonists where applicable)

Trial populations often had prior DMARD failure; document prior treatments

Safety screening and contraindications: Evidence of screening for latent tuberculosis and viral hepatitis prior to initiation and documentation that abatacept will not be given concomitantly with TNF antagonists or other disallowed biologic RA therapies

TB screening within 6 months for biologic‑naive patients; avoid concomitant TNF antagonists per label

Pediatric coverage

Pediatric dosing and coverage considerations

Pediatric age and dosing guidance: Subcutaneous abatacept is approved for juvenile idiopathic arthritis and psoriatic arthritis for patients 2 years of age and older. Intravenous pediatric dosing (6–17 years): 10 mg/kg for patients weighing <75 kg; patients ≥75 kg follow adult dosing (maximum 1,000 mg). Infusion schedule: initial, weeks 2 and 4 after first infusion, then every 4 weeks thereafter.age >=2 years; weight‑based dosing as specified

SC approval age and IV pediatric dosing per labeling and trials

Pediatric prior therapy relevance: Clinical pediatric trials generally enrolled patients who had failed one or more DMARDs; documentation of prior DMARD failure may be relevant to coverage determinations despite labeling allowing use without prior DMARDs

Trial populations focused on DMARD‑refractory patients

Covered Indications and Required Documentation

Covered when ALL of the following are met (based on evidence and FDA labeling in these sections):

Coverage - juvenile idiopathic arthritis: Patient has a diagnosis of polyarticular juvenile idiopathic arthritis for which abatacept is FDA‑approved; dosing will follow age‑ and weight‑based recommendations; clinical justification provided (e.g., inadequate response to prior DMARDs or biologics as applicable)age/weight per labeling

Pediatric IV dosing: 10 mg/kg for 6–17 years <75 kg; >=75 kg use adult regimen (max 1000 mg)

Coverage - psoriatic arthritis: Patient has active psoriatic arthritis consistent with trial populations and documentation of prior DMARD therapy where applicable; pediatric SC formulation approval (>=2 years) noted and dosing per labeling will be followedclinical activity documented

Responses observed regardless of prior TNF inhibitor use in trials

Coverage - prophylaxis of aGVHD:

Evidence summary by indication

Summary of clinical evidence and implied coverage considerations by indication

Type 1 diabetes (recent onset): Randomized double‑blind trial showed abatacept slowed decline in C‑peptide over 2 years with an estimated delay in C‑peptide reduction, but effect attenuated after 6 months and longer‑term implications remain uncertain

Orban et al. 2011; n=112 randomized (2:1)

Giant cell arteritis: Small randomized double‑blind trial (n=49) demonstrated reduced relapse rate and longer median remission with abatacept versus placebo when added to prednisone, but sample size was small and follow‑up limited

Langford et al. 2017a

Dermatomyositis/Polymyositis: Pilot randomized/delayed‑start trial in refractory adult dermatomyositis/polymyositis showed preliminary signals of benefit in a small cohort (n≈20) that require phase‑III confirmation

Tjamlund et al. 2018

Coverage stance for off-label/other indications

Coverage for abatacept in these indications is generally investigational or supported only in limited circumstances; the document presents condition‑specific evidence summaries rather than formal coverage criteria.

FSGS/Nephrotic syndromes (TRNS): Abatacept has been used in case reports/series for primary and recurrent FSGS and treatment‑resistant nephrotic syndrome; evidence is mixed and may depend on podocyte B7‑1 (CD80) staining status; randomized trials are planned and biomarker‑guided use may be required in study contextsbiopsy/biomarker evidence may be required in trials

Evidence uncertain; trial planned (Trachtman et al.)

Localized scleroderma / Morphea: Small uncontrolled series in juvenile and adult localized scleroderma report clinical improvement with abatacept in treatment‑resistant cases; evidence quality is low and routine coverage is investigationalprior failure of standard therapies and documented disease activity scores (LoSCAT, MRSS)

Small series and high risk of bias

Other Indications — evidence summaries

Evidence summaries for other indications of abatacept:

Rheumatoid pleural effusion: Single‑case report described resolution of refractory rheumatoid pleural effusion after abatacept; preliminary evidence onlycase report only

Fujita et al. 2018

Rheumatoid vasculitis: Isolated case report described improvement in cutaneous rheumatoid vasculitis after abatacept when other therapies failed; evidence hypothesis‑generatingcase report only

Al Attar and Shaver 2018

Scleritis: Retrospective series (n=14) including abatacept among other biologics reported improved inflammatory grading and fewer relapses; small heterogeneous cohort and not conclusivesmall retrospective cohort

Use of abatacept concomitantly with any other biologic or targeted synthetic drug for the same indication is considered experimental and investigational because the effectiveness of combined biologic/targeted synthetic therapy has not been established.

The policy lists specific ICD-10 codes not covered for indications listed in the CPB (not an all-inclusive list). Claims using those diagnoses (for example, G35 for multiple sclerosis, the K50.* and K51.* series for Crohn's disease and ulcerative colitis, and codes for psoriasis and morphea) may trigger denial if submitted as the indication for abatacept.

Concurrent administration of abatacept with tumor necrosis factor (TNF) antagonists or other biologic rheumatoid arthritis therapies (for example, anakinra) is contraindicated per labeling and is associated with higher rates of infections; such combination use is not permitted.

Randomized induction and maintenance trials in inflammatory bowel disease demonstrated no consistent benefit for abatacept; the studies showed that abatacept is not efficacious for moderate-to-severe Crohn's disease or ulcerative colitis and coverage for these indications is not supported.

Multiple UpToDate reviews and guideline summaries for several conditions do not list abatacept as a therapeutic option (for example, localized scleroderma/morphea and psoriasis), indicating that abatacept is not recognized as a standard treatment for these conditions in current reviews.

In a randomized, double-blind, multicenter trial for Takayasu arteritis, abatacept did not increase relapse-free survival versus placebo and did not prolong median remission; the trial therefore did not demonstrate efficacy for TAK.

These document segments include appendices, references, and policy administrative language but do not list any additional explicit coverage exclusions beyond those described elsewhere in the CPB.

The Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is not a contract; statements in the CPB (including the abbreviated coverage descriptions in this bulletin) are for administrative guidance and do not by themselves create contractual rights or obligations.

For members who are new to targeted immune modulators, Orencia IV (intravenous abatacept) is considered medically necessary only when a documented contraindication, intolerance, or ineffective response to specified lower-cost alternative targeted immune modulators is present; otherwise IV brand selection restrictions may result in noncoverage.

Combination therapy of abatacept with a TNF antagonist is considered not medically necessary because trials showed increased rates of infections and serious infections without improved effectiveness.

The randomized trial program for Crohn's disease and ulcerative colitis found no consistent clinical benefit for abatacept; as a result, abatacept is considered not medically necessary for moderate-to-severe Crohn's disease and ulcerative colitis.

The policy reiterates that evidence does not support abatacept use in Crohn's disease or ulcerative colitis and that coverage for these indications is not supported by randomized trial data.

There is insufficient evidence to support abatacept for certain autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus; these indications are unsupported outside of clinical trials.

Available data for axial spondyloarthropathies come from small series and limited studies that did not show meaningful benefit; abatacept for axial forms of spondyloarthritis is therefore generally not supported by current evidence.

This portion of the document (appendix material and references) does not contain explicit new 'not medically necessary' criteria; it mainly provides supporting appendices and bibliographic information.

Coding — HCPCS, J‑codes, ICD‑10 and Dosing Notes

Covered CPT/HCPCS and related codesmixedCovered

71045-71048	Radiologic examination, chest
85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)
86200	Cyclic citrullinated peptide (CCP), antibody
86430	Rheumatoid factor; qualitative
86431	Rheumatoid factor; quantitative
86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
86481	Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T cells in cell suspension

1–10 of 14

1/2

Other HCPCS codes referencedHCPCS

J0135	Injection, adalimumab, 20 mg
J0717	Injection, certolizumab pegol, 1 mg
J1745	Injection, infliximab, 10 mg
Q5103	Injection, infliximab-dyyb (Inflectra), 10 mg
Q5104	Injection, infliximab-abda (Renflexis), 10 mg
Q5109	Injection, infliximab-qbtx (Ixifi), 10 mg
J9312	Injection, rituximab, 10 mg
Q5115	Injection, rituximab-abbs (Truxima), 10 mg

HCPCS / J-codes (group 1)HCPCS

J1020	Injection, methylprednisolone acetate, 20 mg
J1030	Injection, methylprednisolone acetate, 40 mg
J1040	Injection, methylprednisolone acetate, 80 mg
J1094	Injection, dexamethasone acetate, 1 mg
J1100	Injection, dexamethasone sodium phosphate, 1 mg
J1438	Injection, etanercept, 25 mg
J1600	Injection, gold sodium thiomalate, up to 50 mg
J1700	Injection, hydrocortisone acetate, up to 25 mg
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg

1–10 of 22

1/3

HCPCS / J- and Q-codes (group 2)HCPCS

J7500	Azathioprine, oral, 50 mg
J7501	Azathioprine, parenteral, 100 mg
J7509	Methylprednisolone oral, per 4 mg
J7510	Prednisolone oral, per 5 mg
J7512	Prednisone, immediate release or delayed release, oral, 1 mg
J8540	Dexamethasone, oral, 0.25 mg
J8610	Methotrexate, oral, 2.5 mg
J9250	Methotrexate sodium, 5 mg
J9255	Injection, methotrexate (accord) not therapeutically equivalent to J9250 or J9260, 50 mg
J9260	Methotrexate sodium, 50 mg

1–10 of 18

1/2

Biosimilar Q-codesHCPCS

Q5131	Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg
Q5132	Injection, adalimumab-afzb (Abrilada), biosimilar, 10 mg

Covered ICD-10 codes if selection criteria metICD-10Covered

D89.811	Chronic graft-versus-host disease
D89.812	Acute on chronic graft-versus-host disease
I40.0 - I40.9	Acute myocarditis [immune checkpoint inhibitor-related cardiac toxicity]
I41	Myocarditis in diseases classified elsewhere [immune checkpoint inhibitor-related cardiac toxicity]
L40.50 - L40.59	Arthropathic psoriasis [age 2 and older]
M05.00 - M05.09; M05.20 - M06.39; M06.80 - M06.9	Rheumatoid arthritis [age 18 and older]
M08.00 - M08.9	Juvenile arthritis

ICD-10 codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered

D83.0 - D83.9	Common variable immunodeficiency
D89.810	Acute graft-versus-host disease
D89.813	Graft-versus-host disease, unspecified
E10.10 - E10.9	Type 1 diabetes mellitus
G35	Multiple sclerosis
J84.0 - J84.9	Other interstitial pulmonary diseases
H15.091 - H15.099	Other scleritis [non-infectious refractory scleritis]
K50.00 - K50.919	Crohn's disease (regional enteritis)
K51.00 - K51.919	Ulcerative colitis
K68.9	Other disorders of retroperitoneum [encapsulated peritoneal sclerosis]

1–10 of 33

1/4

Coding notesmixed

NDC or HCPCS not specified in this section

No specific billing codes listed in this document portion.

Weight-based dosing thresholds — IV and SC dosing by weight and pediatric bands

Adult IV weight bands<60 kg = 500 mg; 60–100 kg = 750 mg; >100 kg = 1,000 mg (IV schedule: 0, 2, 4 weeks then every 4 weeks)

Pediatric IV dosing (6–17 yrs)<75 kg = 10 mg/kg per infusion; >=75 kg = follow adult IV regimen (max 1,000 mg); schedule: initial, 2 and 4 weeks, then every 4 weeks

Pediatric SC weight bands (2+ yrs)10 to <25 kg = 50 mg weekly; 25 to <50 kg = 87.5 mg weekly; >50 kg = 125 mg weekly (SC, no IV loading dose)

aGVHD IV dosing (>=6 yrs)10 mg/kg IV (max 1,000 mg) on Day -1, and Days 5, 14, and 28 (60-minute infusion)

aGVHD IV dosing (2 to <6 yrs)

Provider Actions, Prior Authorization and Documentation Requirements

Prior Authorization

Prior Authorization Required

Precertification and prior authorization are required for intravenous abatacept (Orencia IV). For precertification of Orencia IV, contact Aetna at (866) 752-7021 or fax (888) 267-3277 and submit the Statement of Medical Necessity (SMN) / prior authorization documentation per plan procedures. Clinical Policy Bulletins (CPBs) and specific plan procedures govern coverage determinations — CPBs assist in administering benefits but do not guarantee coverage or substitute for clinical judgment.

Precertification contact: (866) 752-7021; fax: (888) 267-3277.
Submit Statement of Medical Necessity (SMN) or equivalent prior authorization form as required by plan.

Documentation Required

Indication, Dosing and Transplant Context

Document the requested FDA-approved indication or recognized compendial use, including specific indication, dosing, and transplant context (when applicable). For transplant-related indications (eg, aGVHD prophylaxis), include transplant details: donor type, transplant date, conditioning regimen, and concurrent prophylactic immunosuppression.

Background and Evidence Overview

Abatacept (Orencia) is a selective co‑stimulation modulator (CTLA‑4–Ig fusion protein) available as both an intravenous infusion and subcutaneous injection and is indicated for conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and prophylaxis of acute graft‑versus‑host disease in HSCT recipients. Dosing varies by formulation, indication, age, and weight.

Definitions, Formulations and Dosing

Orencia IV and SC preparations — formulations and presentations

IV presentation250 mg lyophilized powder in single‑dose vial for reconstitution (used to prepare IV infusion)

SC prefilled syringes50 mg/0.4 mL; 87.5 mg/0.7 mL; 125 mg/mL single‑dose prefilled syringes

SC ClickJect autoinjector125 mg/mL solution in a single‑dose prefilled ClickJect autoinjector

Dosing summary — dosing varies by indication, age, weight with IV weight-based regimens and SC dosing

Route and regimen vary by indicationDosing and route (IV vs SC) differ by indication, age, and weight; IV regimens are weight‑based and SC doses are fixed or weight‑banded in pediatrics

Adult IV regimenIV: weight‑based dosing at 0, 2, 4 weeks then every 4 weeks (30‑minute infusion)

Policy Dates and Revision History

Precertification (prior authorization) is required for intravenous abatacept (Orencia IV). Providers should contact Aetna's precertification resources and submit clinical documentation, including the Statement of Medical Necessity and supporting records, as applicable.